Int. j. adv. multidisc. res. stud. 2024; 4(6):2488-2493

Received: 11-11-2024
Accepted: 21-12-2024

International Journal of Advanced Multidisciplinary Research and Studies

ISSN: 2583-049X

Improving Platelet Function for Better Management of Hemostasis and Thrombosis

[1] **Tolulope Bolarinwa,** [2] **Opeoluwa Oluwanifemi Akomolafe**
[1] Independent Researcher, Indiana, USA
[2] Independent Researcher, UK

DOI: https://doi.org/10.62225/2583049X.2024.4.6.4485
Corresponding Author: **Tolulope Bolarinwa**

Abstract
Platelet function plays a critical role in maintaining hemostasis and preventing pathological thrombosis. This review explores current knowledge and emerging strategies to enhance platelet function for improved management of hemostatic and thrombotic disorders. The platelet activation and aggregation mechanisms are examined, highlighting key signaling pathways and factors influencing these processes. Current therapeutic approaches, including antiplatelet drugs and their limitations, are discussed, along with novel targets such as protease-activated receptors and genetic interventions. Innovations in drug development, including nanotechnology and targeted delivery systems, are explored for their potential to optimize platelet function while minimizing adverse effects. Clinical implications focus on strategies to enhance hemostasis in surgical and trauma patients, manage thrombotic disorders effectively, and advance personalized medicine through tailored treatments based on individual platelet profiles. Future research needs include identifying genetic markers and further elucidating complex platelet interactions to refine therapeutic strategies. Ultimately, improving platelet function holds promise for reducing cardiovascular events and enhancing patient outcomes, underscoring the importance of integrating new therapies into clinical practice.

Keywords: Platelet Function, Hemostasis, Thrombosis, Antiplatelet Drugs, Personalized Medicine, Drug Development

1. Introduction

Hemostasis and thrombosis are critical physiological processes that maintain the integrity of the circulatory system. Hemostasis is the process by which the body stops bleeding at the site of an injury, involving a complex interplay between blood vessels, platelets, and the coagulation cascade (Henson & Smith, 2020) [16]. Thrombosis, on the other hand, is the formation of a blood clot within a blood vessel, potentially leading to conditions such as heart attacks, strokes, and venous thromboembolism. Both processes are essential for survival but require a delicate balance to prevent excessive bleeding or unwarranted clot formation (Alkarithi, Duval, Shi, Macrae, & Ariëns, 2021) [1].

Platelets, also known as thrombocytes, are small, anucleate cell fragments derived from megakaryocytes in the bone marrow. They play a pivotal role in hemostasis by adhering to the site of vascular injury, aggregating with each other, and forming a stable platelet plug. This plug is a temporary barrier to blood loss while the coagulation cascade is activated to form a more durable fibrin clot. The importance of platelet function in hemostasis cannot be overstated; without proper platelet activity, even minor injuries could lead to significant blood loss, and defective platelet function can result in bleeding disorders such as hemophilia and von Willebrand disease (Maouia, Rebetz, Kapur, & Semple, 2020) [22].

Despite the critical role of platelets in maintaining hemostasis, their function must be tightly regulated to prevent pathological thrombosis. Conditions like atherosclerosis, atrial fibrillation, and certain genetic disorders can predispose individuals to excessive platelet activation and aggregation, leading to thrombotic events. Managing these conditions presents significant challenges in clinical practice, as the goal is to inhibit pathological clot formation without impairing the essential hemostatic functions of platelets.

Current therapies for managing hemostasis and thrombosis include a range of antiplatelet drugs, anticoagulants, and thrombolytics. However, these treatments often come with limitations and risks. Antiplatelet drugs like aspirin and clopidogrel reduce the risk of thrombotic events but can increase the risk of bleeding (Mackman, Bergmeier, Stouffer, & Weitz, 2020) [21].

Anticoagulants, such as warfarin and direct oral anticoagulants, reduce clot formation and carry a significant bleeding risk. Thrombolytics, used to dissolve existing clots, can lead to severe hemorrhagic complications. These challenges highlight the need for more precise and effective strategies to improve platelet function for better management of hemostasis and thrombosis (Li, Yuan, & Yuan, 2020; Mackman *et al*., 2020) [18, 21].

The primary objective of this paper is to explore and evaluate strategies for improving platelet function, aiming to enhance their hemostatic role while minimizing the risk of thrombosis. By understanding the underlying mechanisms of platelet activation and aggregation, identifying novel therapeutic targets, and assessing the clinical implications of improved platelet function, we hope to pave the way for more effective and safer management of hemostasis and thrombosis. Improving platelet function has significant implications for clinical outcomes, as it can lead to better management of bleeding disorders, reduce the incidence of thrombotic events, and ultimately improve the quality of life for patients with hemostatic and thrombotic disorders.

2. Mechanisms of Platelet Activation and Aggregation

2.1 Platelet Biology

Platelets, or thrombocytes, are small, anucleate cell fragments derived from megakaryocytes in the bone marrow. Despite their lack of a nucleus, platelets contain a variety of organelles, including mitochondria, granules, and an extensive cytoskeletal network, which enable them to perform their critical functions. The primary role of platelets is to maintain hemostasis, a process that prevents excessive bleeding following vascular injury (Sang, Roest, de Laat, de Groot, & Huskens, 2021) [27].

In normal hemostasis, platelets adhere to the exposed extracellular matrix of a damaged blood vessel. This adhesion is mediated by the binding of platelet surface glycoproteins to von Willebrand factor (vWF) and collagen in the subendothelial matrix (Mojzisch & Brehm, 2021) [23]. Once adhered, platelets become activated, undergoing a shape change from a discoid to a more spherical form with extended filopodia. This transformation increases the surface area for interaction with other platelets and the coagulation factors, setting the stage for aggregation and the formation of a stable platelet plug (Zhang, Liu, & Liu, 2024) [38].

2.2 Pathways of Platelet Activation

Platelet activation is a complex process regulated by multiple signaling pathways. Key among these are the pathways mediated by thrombin, collagen, and adenosine diphosphate (ADP). Thrombin, generated during the coagulation cascade, is a potent platelet activator that binds to protease-activated receptors (PARs) on the platelet surface, initiating intracellular signaling cascades. This results in the release of calcium from intracellular stores, activation of phospholipase C (PLC), and generation of diacylglycerol (DAG) and inositol trisphosphate (IP3), which amplify the activation signal (Scridon, 2022) [28].

Collagen, exposed at the site of vascular injury, binds to the glycoprotein VI (GPVI) receptor on platelets, activating Src family kinases and the subsequent activation of the PLCγ2 pathway. This signaling cascade also results in calcium mobilization and protein kinase C (PKC) activation, promoting platelet activation and secretion of granule contents (Harbi, Smith, Nicolson, Watson, & Thomas, 2021) [15]. ADP, released from dense granules of activated platelets, binds to purinergic receptors P2Y1 and P2Y12 on the platelet surface. Activation of P2Y1 leads to shape change and initial aggregation, while P2Y12 activation sustains aggregation and stabilizes the platelet plug. These signaling pathways do not act in isolation but interact synergistically to ensure a robust platelet activation response.Platelets also interact with other components of the coagulation system, amplifying the hemostatic response. Activated platelets provide a phospholipid surface essential for assembling coagulation complexes, catalyzing prothrombin conversion to thrombin. Thrombin, in turn, further activates platelets, creating a positive feedback loop that rapidly amplifies the hemostatic response (Gąsecka *et al*., 2020; Poddar & Banerjee, 2020) [11, 25].

2.3 Platelet Aggregation

The platelet aggregation process is crucial for forming a stable hemostatic plug. Platelets express integrin αIIbβ3 (also known as glycoprotein IIb/IIIa) on their surface after activation. This integrin binds fibrinogen, a soluble plasma protein, forming bridges between adjacent platelets and facilitating their aggregation. Fibrinogen binding induces a conformational change in αIIbβ3, increasing its affinity for fibrinogen and other adhesive ligands (Buitrago, Lefkowitz, Bentur, Padovan, & Coller, 2021) [6]. Several factors influence platelet aggregation, including the local concentration of agonists, shear stress, and the availability of adhesive proteins. Agonists such as thrombin, ADP, and thromboxane A2 (TxA2) significantly promote aggregation (Lu *et al*., 2022) [19]. Thromboxane A2, synthesized and released by activated platelets, acts in an autocrine and paracrine manner to enhance platelet activation and aggregation. It binds to the thromboxane receptor on platelets, triggering additional signaling pathways that reinforce the aggregation process (Trigani, DeCortin, & Diamond, 2022; Wolberg & Sang, 2022) [31, 37].

Shear stress, generated by blood flow, also influences platelet aggregation. Under high shear conditions, such as those found in the arterial circulation, the interaction between vWF and the glycoprotein Ib-IX-V complex on platelets becomes more critical. This interaction helps tether platelets to the site of vascular injury, particularly under conditions where fibrinogen binding might be less effective (Sang *et al*., 2021) [27]. Moreover, the availability of adhesive proteins like fibrinogen and vWF is essential for effective platelet aggregation. Fibrinogen serves as a bridge between platelets, while vWF stabilizes platelet adhesion and supports aggregation under high-shear conditions. The balance between pro-aggregatory and anti-aggregatory factors determines the extent and stability of platelet aggregation, which is crucial for effective hemostasis without pathological thrombosis (Avdonin *et al*., 2021; Bendas & Schlesinger, 2022) [2, 4].

In summary, platelet activation and aggregation mechanisms are highly complex and tightly regulated processes essential for maintaining hemostasis. Understanding the biology of platelets, the signaling pathways involved in their activation, and the factors influencing their aggregation provides crucial insights into developing strategies for improving platelet function. Such advancements hold significant potential for better management of hemostasis and thrombosis, offering hope for more effective and safer therapeutic interventions.

3. Therapeutic Targets for Enhancing Platelet Function
3.1 Current Therapeutic Approaches
Antiplatelet drugs are a cornerstone in the management of thrombotic disorders, playing a crucial role in preventing arterial thrombosis, which can lead to heart attacks and strokes. These drugs work by inhibiting various pathways involved in platelet activation and aggregation. The most commonly used antiplatelet drugs include aspirin, P2Y12 inhibitors, and glycoprotein IIb/IIIa inhibitors.

Aspirin is an irreversible cyclooxygenase-1 (COX-1) inhibitor, an enzyme crucial for synthesizing thromboxane A2 (TxA2). TxA2 is a potent promoter of platelet aggregation and vasoconstriction (Ferreira *et al*., 2020; Szczuko, Kozioł, Kotlęga, Brodowski, & Drozd, 2021) [9, 29]. By inhibiting COX-1, aspirin reduces the production of TxA2, thereby diminishing platelet activation and aggregation. P2Y12 inhibitors, such as clopidogrel, prasugrel, and ticagrelor, block the ADP receptor P2Y12 on the platelet surface. This inhibition prevents ADP-mediated activation of the integrin αIIbβ3, essential for platelet aggregation. Glycoprotein IIb/IIIa inhibitors, like abciximab, eptifibatide, and tirofiban, directly inhibit the integrin αIIbβ3 receptor, blocking fibrinogen binding and subsequent platelet aggregation (Rikken, van't Hof, Ten Berg, Kereiakes, & Coller, 2023; van den Kerkhof, van der Meijden, Hackeng, & Dijkgraaf, 2021) [26, 33].

Despite their effectiveness, current antiplatelet therapies have limitations. One of the major issues is the increased risk of bleeding, as these drugs interfere with the normal hemostatic process. This can lead to serious complications, especially in patients who require long-term antiplatelet therapy. Moreover, interindividual variability in response to these drugs poses a challenge. Genetic polymorphisms, drug interactions, and comorbid conditions can affect drug efficacy, leading to either insufficient platelet inhibition or excessive bleeding. Additionally, resistance to certain antiplatelet drugs, particularly clopidogrel, has been documented, necessitating the development of alternative therapies (Jourdi, Lordkipanidze, Philippe, Bachelot-Loza, & Gaussem, 2021) [17].

3.2 Novel Therapeutic Targets
To overcome the limitations of current therapies, research has focused on identifying novel molecular targets for improving platelet function. Emerging targets include signaling molecules and receptors pivotal in platelet activation and aggregation. One such target is the protease-activated receptor-1 (PAR-1), activated by thrombin. Inhibiting PAR-1 can provide a more selective approach to prevent platelet activation without significantly affecting other hemostatic processes. Vorapaxar, a PAR-1 antagonist, has shown promise in reducing thrombotic events with a lower bleeding risk compared to traditional antiplatelet drugs.

Genetic and biochemical approaches are also being explored to enhance platelet response. Gene editing technologies like CRISPR/Cas9 can potentially correct genetic defects impairing platelet function. For instance, gene therapy could restore normal platelet function in conditions like Glanzmann thrombasthenia, where there is a deficiency of integrin αIIbβ3. Additionally, targeting microRNAs that regulate platelet gene expression holds potential for fine-tuning platelet activity. Modulating the levels of specific microRNAs could enhance or suppress platelet function as needed for therapeutic purposes (Czajka *et al*., 2021; Garcia *et al*., 2021) [8, 10].

3.3 Innovative Drug Development
Advances in drug design are paving the way for developing new therapies to improve platelet function. One promising area is the development of drugs that can modulate platelet activity more precisely. For example, allosteric modulators of platelet receptors offer the potential to fine-tune receptor activity, providing a more balanced approach to platelet inhibition. These modulators can partially inhibit platelet function, reducing the risk of bleeding while protecting against thrombosis (Ghose, Swain, Patra, Jena, & Rao, 2023; Ma *et al*., 2021) [13, 20].

Another innovative approach is the development of nanoparticles and drug-delivery systems that target platelets selectively. By designing nanoparticles that can deliver antiplatelet drugs directly to activated platelets at the site of vascular injury, it is possible to enhance the efficacy of these drugs while minimizing systemic side effects. These targeted delivery systems can improve the therapeutic index of antiplatelet agents, making them safer and more effective (Wan *et al*., 2020) [35]. Additionally, research explores the potential of combining antiplatelet drugs with other therapies to achieve synergistic effects. For instance, combining antiplatelet agents with anticoagulants or anti-inflammatory drugs could provide comprehensive protection against thrombotic events while mitigating the limitations of each therapy. This combination therapy approach requires careful optimization to balance efficacy and safety, but it holds significant promise for improving patient outcomes (Capodanno & Angiolillo, 2020; Tsoupras *et al*., 2024) [7, 32].

The potential benefits of these new therapies are substantial. They offer the possibility of more effective and safer management of thrombotic disorders, reducing the incidence of heart attacks, strokes, and other thrombotic events. Improved platelet function can also enhance the quality of life for patients with bleeding disorders by reducing the risk of excessive bleeding during medical procedures or trauma.However, the development of these therapies also presents challenges and risks. The complexity of platelet biology means that targeting specific pathways can have unintended consequences, affecting other aspects of hemostasis or causing off-target effects. Rigorous preclinical and clinical testing is essential to ensure the safety and efficacy of these new therapies. Additionally, the cost and accessibility of advanced therapies, such as gene editing and targeted drug delivery systems, must be considered to ensure they can benefit a broad range of patients (Bae & Park, 2020; van Haasteren, Li, Scheideler, Murthy, & Schaffer, 2020) [3, 34].

4. Clinical Implications and Applications
4.1 Improving Hemostasis
Enhancing the hemostatic response is crucial in surgical and trauma settings to minimize blood loss and improve patient outcomes. Strategies focus on optimizing platelet function, which plays a central role in the initial stages of hemostasis. Platelets adhere to the injured vessel wall, become activated, and aggregate to form a plug that seals the breach. Preemptive measures such as platelet transfusions or

pharmacological agents like desmopressin (DDAVP) augment platelet function and reduce bleeding risks in surgical procedures. These approaches particularly benefit patients with congenital or acquired platelet function defects, such as von Willebrand disease or aspirin resistance (Graetz, Nuttall, & Shander, 2023) [14].

Platelet function is equally critical in managing bleeding disorders characterized by impaired hemostasis. Disorders like hemophilia, where deficiencies in clotting factors impair coagulation, often require adjunctive therapies to enhance platelet function. Strategies may include recombinant clotting factors in these cases to initiate coagulation cascades and facilitate platelet activation. Moreover, advancements in gene therapy offer promising avenues for correcting genetic defects underlying bleeding disorders, potentially restoring normal platelet function and improving clinical outcomes for affected individuals (Scridon, 2022; Thakar *et al*., 2021) [28].

4.2 Managing Thrombosis

In contrast to bleeding disorders, managing thrombotic disorders involves balancing platelet activation and inhibition to prevent pathological clot formation. Excessive platelet activation and aggregation contribute to conditions such as myocardial infarction, stroke, and venous thromboembolism. Antiplatelet therapies, such as aspirin and P2Y12 inhibitors, are cornerstone treatments aimed at inhibiting platelet function and reducing the risk of thrombotic events. These therapies are especially effective in preventing arterial thrombosis by interfering with pathways that promote platelet aggregation and vascular occlusion (Gawaz, Geisler, & Borst, 2023; Passacquale, Sharma, Perera, & Ferro, 2022) [12, 24].

Improved platelet function has a profound impact on thrombotic event prevention. By enhancing platelet responsiveness to antiplatelet therapies or targeting specific molecular pathways involved in thrombosis, clinicians can effectively manage thrombotic disorders more effectively. Novel therapies targeting receptors like PAR-1 or innovative drug delivery systems promise to enhance efficacy while minimizing adverse effects associated with current antiplatelet agents. Additionally, advances in personalized medicine allow for tailoring treatments based on individual patient profiles, optimizing therapeutic outcomes, and reducing the risk of complications (Bizzarri *et al*., 2021; Wang & Wang, 2023) [5, 36].

4.3 Personalized Medicine

Personalized medicine represents a paradigm shift in hemostasis and thrombosis management, moving away from a one-size-fits-all approach to tailored treatments based on individual patient characteristics. The variability in platelet function among patients underscores the importance of personalized approaches in optimizing therapeutic efficacy and safety. Biomarkers such as platelet function assays and genetic testing provide valuable insights into an individual's hemostatic profile, guiding treatment decisions and predicting responses to antiplatelet therapies.

Tailoring treatments based on individual platelet function profiles allows clinicians to optimize antiplatelet therapy dosing and selection, reducing the risk of under- or over-treatment. For example, genetic polymorphisms affecting drug metabolism or receptor function can influence the efficacy of antiplatelet agents like clopidogrel. Pharmacogenetic testing enables clinicians to identify patients at higher risk of treatment resistance and adjust therapy accordingly, improving clinical outcomes and reducing adverse events.

Future directions in personalized medicine for hemostasis and thrombosis management include advancing biomarker research and integrating artificial intelligence (AI) technologies into clinical practice. AI-driven algorithms can analyze complex datasets, such as genetic profiles and clinical variables, to predict individualized responses to antiplatelet therapies. This predictive modeling enhances treatment precision and identifies optimal therapeutic strategies for patients with diverse hemostatic and thrombotic conditions.Moreover, ongoing research in nanotechnology and drug delivery systems aims to develop targeted therapies that deliver antiplatelet agents directly to activated platelets or thrombotic sites. These advancements improve drug efficacy and minimize systemic side effects, enhancing patient safety and treatment adherence. As personalized medicine evolves, interdisciplinary collaboration between clinicians, geneticists, pharmacologists, and bioengineers will translate research findings into clinical practice and improve outcomes for patients with hemostatic and thrombotic disorders.

5. Conclusion and Future Directions

5.1 Summary of Key Points

Platelet function is integral to maintaining hemostasis and preventing pathological thrombosis within the circulatory system. These small, anucleate cell fragments play a pivotal role in the initial response to vascular injury, adhering to exposed collagen and other extracellular matrix components, becoming activated, and forming aggregates that seal breaches in blood vessel walls. This process is essential for preventing excessive bleeding while avoiding unwarranted clot formation.

Improving platelet function represents a critical area of research to enhance therapeutic outcomes in managing bleeding disorders and thrombotic conditions. Current strategies involve antiplatelet drugs inhibiting pathways such as cyclooxygenase-1 (COX-1) and adenosine diphosphate (ADP) receptors, reducing platelet activation and aggregation. However, these therapies have limitations, including increased bleeding risks and variable responses among patients, necessitating the exploration of novel therapeutic targets and approaches.

5.2 Future Research Needs

Despite significant advancements, gaps in our understanding of platelet biology and the mechanisms underlying platelet dysfunction remain. Further research is needed to elucidate the intricate signaling pathways involved in platelet activation and aggregation and the interplay between platelets and other coagulation cascade components. Identifying specific genetic and biochemical markers associated with platelet function variability will enable personalized medicine approaches tailored to individual patient profiles, optimizing treatment efficacy and safety.

Future research should also focus on developing innovative therapies that target novel molecular pathways implicated in platelet activation and thrombus formation. This includes exploring the role of emerging targets such as protease-activated receptors (PARs) and microRNAs in modulating platelet function. Advances in nanotechnology and drug delivery systems offer promising opportunities to enhance the specificity and efficacy of antiplatelet therapies, delivering agents directly to activated platelets or thrombotic sites while minimizing off-target effects.

The expected impact of improved platelet function on patient outcomes is substantial. Enhanced therapies that effectively balance hemostasis and thrombosis can reduce the incidence of cardiovascular events, strokes, and other thrombotic complications, improving the overall quality of life for patients with thrombotic disorders. Tailoring treatments based on individual platelet function profiles will enable clinicians to achieve better outcomes with reduced risks of bleeding or treatment resistance.Integrating new strategies into clinical practice requires collaborative efforts among researchers, clinicians, and pharmaceutical developers. Robust clinical trials and real-world studies are essential to validate emerging therapies' efficacy, safety, and cost-effectiveness before widespread adoption. Furthermore, education and training programs for healthcare providers are crucial to ensure optimal implementation and adherence to new treatment guidelines.

6. References

1. Alkarithi G, Duval C, Shi Y, Macrae FL, Ariëns RA. Thrombus structural composition in cardiovascular disease. Arteriosclerosis, thrombosis, and vascular biology. 2021; 41(9):2370-2383.
2. Avdonin P, Tsvetaeva N, Goncharov N, Rybakova EY, Trufanov S, Tsitrina A, *et al*. Von Willebrand Factor in Health and Disease. Biochemistry (Moscow), Supplement Series A: Membrane and Cell Biology. 2021; 15(3):201-218.
3. Bae YH, Park K. Advanced drug delivery 2020 and beyond: Perspectives on the future. Advanced drug delivery reviews. 2020; 158:4-16.
4. Bendas G, Schlesinger M. The GPIb-IX complex on platelets: Insight into its novel physiological functions affecting immune surveillance, hepatic thrombopoietin generation, platelet clearance and its relevance for cancer development and metastasis. Experimental Hematology & Oncology. 2022; 11(1):19.
5. Bizzarri M, Fedeli V, Monti N, Cucina A, Jalouli M, Alwasel SH, Harrath AH. Personalization of medical treatments in oncology: Time for rethinking the disease concept to improve individual outcomes. EPMA Journal, 2021, 1-14.
6. Buitrago L, Lefkowitz S, Bentur O, Padovan J, Coller B. Platelet binding to polymerizing fibrin is avidity driven and requires activated αIIbβ3 but not fibrin cross-linking. Blood Advances. 2021; 5(20):3986-4002.
7. Capodanno D, Angiolillo DJ. Antithrombotic therapy for atherosclerotic cardiovascular disease risk mitigation in patients with coronary artery disease and diabetes mellitus. Circulation. 2020; 142(22):2172-2188.
8. Czajka P, Fitas A, Jakubik D, Eyileten C, Gasecka A, Wicik Z, *et al*. MicroRNA as potential biomarkers of platelet function on antiplatelet therapy: A review. Frontiers in physiology. 2021; 12:652579.
9. Ferreira M, Freitas-Silva M, Assis J, Pinto R, Nunes JP, Medeiros R. The emergent phenomenon of aspirin resistance: Insights from genetic association studies. Pharmacogenomics. 2020; 21(2):125-140.
10. Garcia A, Dunoyer-Geindre S, Fish RJ, Neerman-Arbez M, Reny J-L, Fontana P. Methods to investigate miRNA function: Focus on platelet reactivity. Thrombosis and haemostasis. 2021; 121(04):409-421.
11. Gąsecka A, Rogula S, Eyileten C, Postuła, M., Jaguszewski MJ, Kochman J, *et al*. Role of P2Y receptors in platelet extracellular vesicle release. International Journal of Molecular Sciences. 2020; 21(17):6065.
12. Gawaz M, Geisler T, Borst O. Current concepts and novel targets for antiplatelet therapy. Nature Reviews Cardiology. 2023; 20(9):583-599.
13. Ghose D, Swain S, Patra CN, Jena BR, Rao MEB. Advancement and Applications of Platelet-inspired Nanoparticles: A Paradigm for Cancer Targeting. Current Pharmaceutical Biotechnology. 2023; 24(2):213-237.
14. Graetz TJ, Nuttall G, Shander A. Perioperative blood management: Strategies to minimize transfusions. U: UpToDate, O'Connor MF, Kleinman S ed. UpToDate [Internet]. Waltham, MA: UpToDate, 2023.
15. Harbi MH, Smith CW, Nicolson PL, Watson SP, Thomas MR. Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases. Platelets. 2021; 32(1):29-41.
16. Henson MS, Smith SA. Disorders of hemostasis. In the Veterinary ICU Book (pp. 731-751): CRC Press, 2020.
17. Jourdi G, Lordkipanidze M, Philippe A, Bachelot-Loza C, Gaussem P. Current and novel antiplatelet therapies for the treatment of cardiovascular diseases. International Journal of Molecular Sciences. 2021; 22(23):13079.
18. Li T, Yuan D, Yuan J. Antithrombotic drugs—pharmacology and perspectives. Coronary artery disease: Therapeutics and drug discovery, 2020, 101-131.
19. Lu P-H, Liao T-H, Chen Y-H, Hsu Y-L, Kuo C-Y, Chan C-C, *et al*. Coumarin derivatives inhibit ADP-induced platelet activation and aggregation. Molecules. 2022; 27(13):4054.
20. Ma Y-S, Xin R, Yang X-L, Shi Y, Zhang D-D, Wang H-M, *et al*. Paving the way for small-molecule drug discovery. American Journal of Translational Research. 2021; 13(3):853.
21. Mackman N, Bergmeier W, Stouffer GA, Weitz JI. Therapeutic strategies for thrombosis: New targets and approaches. Nature reviews Drug discovery. 2020; 19(5):333-352.
22. Maouia A, Rebetz J, Kapur R, Semple JW. The immune nature of platelets revisited. Transfusion medicine reviews. 2020; 34(4):209-220.
23. Mojzisch A, Brehm MA. The manifold cellular functions of von willebrand factor. Cells. 2021; 10(9):2351.
24. Passacquale G, Sharma P, Perera D, Ferro A. Antiplatelet therapy in cardiovascular disease: Current status and future directions. British Journal of Clinical Pharmacology. 2022; 88(6):2686-2699.
25. Poddar MK, Banerjee S. Molecular aspects of pathophysiology of platelet receptors. Platelets, 2020.
26. Rikken SA, van't Hof AW, Ten Berg JM, Kereiakes DJ, Coller BS. Critical Analysis of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the

Mechanism (s). Journal of the American Heart Association. 2023; 12(24):e031855.
27. Sang Y, Roest M, de Laat B, de Groot PG, Huskens D. Interplay between platelets and coagulation. Blood reviews. 2021; 46:100733.
28. Scridon A. Platelets and their role in hemostasis and thrombosis—From physiology to pathophysiology and therapeutic implications. International Journal of Molecular Sciences. 2022; 23(21):12772.
29. Szczuko M, Kozioł I, Kotlęga D, Brodowski J, Drozd A. The role of thromboxane in the course and treatment of ischemic stroke. International Journal of Molecular Sciences. 2021; 22(21):11644.
30. Thakar S, Gabarin N, Gupta A, Radford M, Warkentin TE, Arnold DM. Anemia-induced bleeding in patients with platelet disorders. Transfusion medicine reviews. 2021; 35(3):22-28.
31. Trigani KT, DeCortin ME, Diamond SL. ADP and thromboxane inhibitors both reduce global contraction of clot length, while thromboxane inhibition attenuates internal aggregate contraction. TH Open. 2022; 6(02):e135-e143.
32. Tsoupras A, Gkika DA, Siadimas I, Christodoulopoulos I, Efthymiopoulos P, Kyzas GZ. The Multifaceted Effects of Non-Steroidal and Non-Opioid Anti-Inflammatory and Analgesic Drugs on Platelets: Current Knowledge, Limitations, and Future Perspectives. Pharmaceuticals. 2024; 17(5):627.
33. van den Kerkhof DL, van der Meijden PE, Hackeng TM, Dijkgraaf I. Exogenous integrin αIIbβ3 inhibitors revisited: past, present and future applications. International Journal of Molecular Sciences. 2021; 22(7):3366.
34. van Haasteren J, Li J, Scheideler OJ, Murthy N, Schaffer DV. The delivery challenge: Fulfilling the promise of therapeutic genome editing. Nature biotechnology. 2020; 38(7):845-855.
35. Wan Q, Qian S, Huang Y, Zhang Y, Peng Z, Li Q, *et al*. Drug discovery for coronary artery disease. Coronary artery disease: Therapeutics and drug discovery, 2020, 297-339.
36. Wang RC, Wang Z. Precision medicine: Disease subtyping and tailored treatment. Cancers. 2023; 15(15):3837.
37. Wolberg AS, Sang Y. Fibrinogen and factor XIII in venous thrombosis and thrombus stability. Arteriosclerosis, thrombosis, and vascular biology. 2022; 42(8):931-941.
38. Zhang H, Liu Y, Liu Z. Nanomedicine approaches against SARS-CoV-2 and variants. Journal of Controlled Release. 2024; 365:101-111.